Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of Patidegib Topical Gel 2% in basal cell nevus syndrome
2018-001462-42Phase 3Completed
- Sponsor
- PellePharm
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Basal cell nevus syndrome (BCNS) and basal cell carcinoma (BCC) comparing Patidegib 2% gel with Vehicle control (2 arms). Primary endpoint: Number of new surgically eligible basal cell carcinomas at 12 months. Started Oct 2018; status: completed.
02
Drugs
patidegib
03
Conditions
Basal cell nevus syndrome (BCNS)basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2018-001462-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001462-42.